BIOLOGY-BASED COMPANIES
Jeff launched Paragon Biosciences in 2017 to accelerate scientific breakthroughs with the potential to solve some of society’s most challenging medical problems.
Through Paragon, he focuses on advancing science to address critical unmet needs for patients. He is currently founder and chairman of several Paragon portfolio companies, including Harmony Biosciences, Emalex Biosciences and CiRC Biosciences.
Jeff’s passion for pharmaceutical development began when he shadowed a physician treating a child with epilepsy. A new medication allowed the patient to avoid life-altering surgery, inspiring Jeff to dedicate his career to developing innovative therapies for patients whose medical needs are unmet.
BIOLOGY BASED COMPANIES
Jeff launched Paragon Biosciences in 2017 to accelerate scientific breakthroughs with the potential to solve some of society’s most challenging medical problems.
Through Paragon, he created life sciences companies focused on meeting critical unmet needs in healthcare. He is currently founder and chairman of several Paragon portfolio companies, including Harmony Biosciences, Emalex Biosciences, Castle Creek Biosciences, CiRC Biosciences and Evozyne.
Jeff’s passion for pharmaceutical development began when he shadowed a physician treating a child with epilepsy. A new medication allowed the patient to avoid life-altering surgery, inspiring Jeff to dedicate his career to developing innovative therapies for patients whose medical needs are unmet.
Paragon Biosciences is among the life science industry’s most successful company creators, investing billions with its partners to build companies that focus on cell and gene therapy, biology engineering, and advanced biotech businesses.
Jeff and his team at Paragon Biosciences have earned five full FDA approvals in neurology, an accomplishment of which he is especially proud. He is known for innovating, developing and commercializing scientific discoveries in areas of high need.
Throughout his career, Jeff has been recognized with numerous awards and honors, including Entrepreneur of the Year-Pharmaceuticals by the American Business Awards®, a Gold Stevie Award and a Titan Award for biology-based innovation. He serves on the board of Discover Financial Services, the Aspen Institute and the Weizmann Institute.
FEATURED COMPANIES
HARMONY BIOSCIENCES
Paragon Biosciences created Harmony Biosciences (NASDAQ; HRMY) in 2017 to develop new treatment options for patients with sleep-wake disorders and other neurological conditions.
EMALEX BIOSCIENCES
Emalex Biosciences was created by Paragon Biosciences to develop new treatments for CNS movement disorders. Emalex is in late-stage development of a new class of drug for patients with Tourette syndrome.
CIRC BIOSCIENCES
Paragon Biosciences founded CiRC Biosciences to develop life-changing regenerative medicines, with an initial goal of restoring vision lost to degenerative retinal diseases.
EVOZYNE
Evozyne creates novel protein systems that enable a healthier world. Evozyne, a Paragon Biosciences portfolio company, confronts critical challenges that impact human and planetary health.
Paragon Biosciences is among the life science industry’s most successful company creators, investing billions with its partners to build companies that improve patient lives through advanced biotechnology.
Jeff and his team at Paragon Biosciences have earned five full FDA approvals in neurology, an accomplishment of which he is especially proud. He is known for innovating, developing and commercializing scientific discoveries in areas of high need.
Throughout his career, Jeff has been recognized with numerous awards and honors, including Entrepreneur of the Year-Pharmaceuticals by the American Business Awards®, a Gold Stevie Award and a Titan Award for biology-based innovation. He serves on the board of Discover Financial Services, the Aspen Institute and the Weizmann Institute.
FEATURED COMPANIES
HARMONY BIOSCIENCES
Paragon Biosciences created Harmony Biosciences (NASDAQ: HRMY) in 2017 to develop new treatment options for patients with sleep-wake disorders and other neurological conditions.
EMALEX BIOSCIENCES
Emalex Biosciences was created by Paragon Biosciences to develop new treatments for CNS movement disorders. Emalex is in late-stage development of a new class of drug for patients with Tourette syndrome.
CiRC BIOSCIENCES
Paragon Biosciences founded CiRC Biosciences to develop life-changing regenerative medicines, with an initial goal of restoring vision lost to degenerative retinal diseases.
EVOZYNE
Evozyne creates novel protein systems that enable a healthier world. Evozyne, a Paragon Biosciences portfolio company, confronts critical challenges that impact human and planetary health.
BIOLOGY BASED COMPANIES
Jeff launched Paragon Biosciences in 2017 to accelerate scientific breakthroughs with the potential to solve some of society’s most challenging medical problems.
Through Paragon, he created life sciences companies focused on meeting critical unmet needs in healthcare. He is currently founder and chairman of several Paragon portfolio companies, including Harmony Biosciences, Emalex Biosciences, Castle Creek Biosciences, CiRC Biosciences and Evozyne.
Jeff’s passion for pharmaceutical development began when he shadowed a physician treating a child with epilepsy. A new medication allowed the patient to avoid life-altering surgery, inspiring Jeff to dedicate his career to developing innovative therapies for patients whose medical needs are unmet.
Paragon Biosciences is among the life science industry’s most successful company creators, investing billions with its partners to build companies that focus on cell and gene therapy, biology engineering, and advanced biotech businesses.
Jeff and his team at Paragon Biosciences have earned five full FDA approvals in neurology, an accomplishment of which he is especially proud. He is known for innovating, developing and commercializing scientific discoveries in areas of high need.
Throughout his career, Jeff has been recognized with numerous awards and honors, including Entrepreneur of the Year-Pharmaceuticals by the American Business Awards®, a Gold Stevie Award and a Titan Award for biology-based innovation. He serves on the board of Discover Financial Services, the Aspen Institute and the Weizmann Institute.
FEATURED COMPANIES
